Bloom Burton Has Strong Outlook for BioSyent FY2025 Earnings

BioSyent Inc. (CVE:RX) – Equities researchers at Bloom Burton increased their FY2025 earnings per share estimates for shares of BioSyent in a note issued to investors on Monday, March 17th. Bloom Burton analyst D. Martin now expects that the company will post earnings of $0.81 per share for the year, up from their previous forecast of $0.80. The consensus estimate for BioSyent’s current full-year earnings is $0.69 per share. Bloom Burton also issued estimates for BioSyent’s FY2027 earnings at $0.94 EPS.

BioSyent Stock Performance

Shares of RX opened at C$11.23 on Tuesday. The stock has a 50-day moving average of C$11.03 and a two-hundred day moving average of C$11.11. BioSyent has a one year low of C$8.24 and a one year high of C$12.13. The company has a debt-to-equity ratio of 2.90, a quick ratio of 6.91 and a current ratio of 3.92. The stock has a market cap of C$128.44 million, a P/E ratio of 18.23 and a beta of 0.93.

Insider Activity

In other news, insider FAX Capital Corp. sold 112,400 shares of the business’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of C$11.28, for a total value of C$1,267,557.28. Insiders own 33.65% of the company’s stock.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.